📗 Cite This Artifact
neurovascular-unit
Neurovascular Unit (NVU)
Introduction
Neurovascular Unit (Nvu) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
The neurovascular unit (NVU) is the functional multicellular complex<a href="#references" class="ref-link" data-ref-number="1" data-ref-text="Iadecola, C. (2010). The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathologica, 120(3), 287-296. https://doi.org/10.1007/s00401-010-0718-6" title="Iadecola, C. (2010). The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathologica, 120(3), 287-296. [DOI))](https://doi.org/10.1007/s00401-010-0718-6))))))))"></a>)) that couples neuronal activity to local cerebral blood flow, maintains [blood-brain-barrier](/entities/blood-brain-barrier) integrity, and regulates the exchange of nutrients, oxygen, and metabolic waste between the brain and the vasculature. The NVU comprises [endothelial-cells](/cell-types/endothelial-cells), [pericytes](/cell-types/pericytes), [astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia)/cell-types/microglia ([Alzheimer et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29377008/)). [@zlokovic2011]
Components of the Neurovascular Unit
Endothelial Cells
...
Neurovascular Unit (NVU)
Introduction
Neurovascular Unit (Nvu) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
The neurovascular unit (NVU) is the functional multicellular complex<a href="#references" class="ref-link" data-ref-number="1" data-ref-text="Iadecola, C. (2010). The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathologica, 120(3), 287-296. https://doi.org/10.1007/s00401-010-0718-6" title="Iadecola, C. (2010). The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathologica, 120(3), 287-296. [DOI))](https://doi.org/10.1007/s00401-010-0718-6))))))))"></a>)) that couples neuronal activity to local cerebral blood flow, maintains [blood-brain-barrier](/entities/blood-brain-barrier) integrity, and regulates the exchange of nutrients, oxygen, and metabolic waste between the brain and the vasculature. The NVU comprises [endothelial-cells](/cell-types/endothelial-cells), [pericytes](/cell-types/pericytes), [astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia)/cell-types/microglia ([Alzheimer et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29377008/)). [@zlokovic2011]
Components of the Neurovascular Unit
Endothelial Cells
Brain endothelial cells form the structural core of the [Blood-Brain Barrier](/entities/blood-brain-barrier) through continuous tight junctions (claudins, occludin, ZO-1), adherens junctions, and specialized transport systems. Unlike peripheral endothelium, brain endothelial cells exhibit minimal pinocytosis, express abundant efflux transporters (P-glycoprotein, BCRP), and maintain low rates of transcytosis. These properties create a highly selective barrier that restricts paracellular and transcellular movement of molecules into the brain parenchyma. [@sweeney2018]
With [aging](/gaps/aging) and neurodegeneration, endothelial tight junctions loosen, transporter expression changes, and transcytosis increases, compromising barrier selectivity. Endothelial cells also become pro-inflammatory, upregulating adhesion molecules (ICAM-1, VCAM-1) that recruit peripheral immune cells into the CNS. [@attwell2010]
Pericytes
[pericytes](/cell-types/pericytes) ensheath brain capillaries, sharing a basement membrane with endothelial cells, and play essential roles in [blood-brain-barrier](/entities/blood-brain-barrier) maintenance, capillary blood flow regulation, angiogenesis, and clearance of toxic metabolites. Brain [pericytes](/cell-types/pericytes) are the most abundant among all organs, with a pericyte-to-endothelial cell ratio of approximately 1:1 to 1:3. [@takano2007]
[Pericyte loss is one of the earliest vascular changes in [alzheimers](/diseases/alzheimers-disease) and [aging](/gaps/aging). Pericyte degeneration leads to [blood-brain-barrier](/entities/blood-brain-barrier) breakdown, reduced cerebral blood flow, and impaired clearance of [amyloid-beta](/proteins/amyloid-beta) and other metabolic waste. Platelet-derived growth factor receptor-β (PDGFRβ) signaling — essential for pericyte survival and recruitment — declines with age, and soluble PDGFRβ in [csf-biomarkers](/diagnostics/csf-biomarkers) has emerged as a biomarker of NVU dysfunction ([Sweeney et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30612862/)) ([Crossing et al., 2025](https://www.aginganddisease.org/EN/10.14336/AD.2025.0801)). [@bell2009]
Astrocytes
[astrocytes](/cell-types/astrocytes) extend specialized endfeet that cover approximately 99% of the brain capillary surface, forming the outer layer of the [blood-brain-barrier](/entities/blood-brain-barrier). Through these endfeet, [astrocytes](/cell-types/astrocytes) regulate water homeostasis via aquaporin-4 (AQP4) channels, modulate tight junction integrity, and control neurovascular coupling — the process by which neuronal activity triggers local vasodilation to increase blood flow ([The et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28957666/)). [@microgliazlokovic2011]
Astrocytic AQP4 channels are essential for the [glymphatic-system](/entities/glymphatic-system), which clears metabolic waste (including [amyloid-beta](/proteins/amyloid-beta) and tau] from the brain during sleep. Loss of AQP4 polarization — the redistribution of AQP4 away from perivascular endfeet — is a hallmark of NVU dysfunction and impairs glymphatic clearance. Reactive astrogliosis, marked by elevated [glial-fibrillary-acidic-protein](/entities/glial-fibrillary-acidic-protein), further disrupts NVU function by altering endfeet morphology and release of vasoactive factors ([Neurovascular et al., 2025](https://www.mdpi.com/1422-0067/26/24/11843)). [@ref]
Microglia
[microglia](/cell-types/microglia) — also termed functional hyperemia — is the process by which neural activity triggers localized increases in cerebral blood flow (CBF). This coupling is essential for delivering oxygen and glucose to active [neurons](/entities/neurons) and for removing metabolic waste. NVC involves coordinated signaling among [neurons](/entities/neurons), interneurons, [astrocytes](/cell-types/astrocytes), [pericytes](/cell-types/pericytes), and vascular smooth muscle cells ([Neurovascular et al., 2025](https://www.sciencepublishinggroup.com/article/10.11648/j.cnn.20250904.11)). [@sweeney2019]
Mechanisms of Neurovascular Coupling
Impaired Neurovascular Coupling in Disease
Neurovascular coupling is impaired early in [alzheimers](/diseases/alzheimers-disease), [vascular-dementia](/diseases/vascular-dementia), and [cerebral-small-vessel-disease](/diseases/cerebral-small-vessel-disease). Functional MRI studies consistently show reduced hemodynamic responses to neural activation in AD patients. This impairment precedes clinical symptoms and may represent one of the earliest detectable changes in the disease process. Impaired NVC reduces the brain's ability to match blood supply to metabolic demand, creating regions of relative hypoperfusion that exacerbate neuronal vulnerability. [@carvalho2025]
NVU Dysfunction in Specific Diseases
Alzheimer's Disease
NVU dysfunction is a central feature of [alzheimers](/diseases/alzheimers-disease) pathogenesis. The two-hit vascular hypothesis proposes that vascular risk factors (hit 1) damage the NVU, which then fails to clear [amyloid-beta](/proteins/amyloid-beta) (hit 2), initiating a self-amplifying cycle of vascular damage and amyloid accumulation ([Zlokovic, 2011](https://pubmed.ncbi.nlm.nih.gov/22048062/)). [@zhang2025]
Key NVU changes in AD include: [@liu2020]
- [blood-brain-barrier](/entities/blood-brain-barrier) breakdown: Occurs in the [hippocampus](/brain-regions/hippocampus) and [entorhinal [cortex](/brain-regions/cortex) early in AD, detectable by dynamic contrast-enhanced MRI and [csf-biomarkers](/diagnostics/csf-biomarkers)
- Pericyte degeneration: Loss of pericytes correlates with tau] pathology] and cognitive decline; PDGFRβ is elevated in CSF of early AD patients
- Impaired [amyloid-beta](/proteins/amyloid-beta) clearance: The NVU clears amyloid-β via [lrp1](/genes/lrp1)-mediated transcytosis, enzymatic degradation ([neprilysin](/proteins/neprilysin), [insulin-degrading enzyme), and perivascular drainage. These pathways decline with NVU dysfunction.
- [cerebral-amyloid-angiopathy](/diseases/cerebral-amyloid-angiopathy): Amyloid deposition in vessel walls reflects failed vascular clearance
- Cerebral hypoperfusion: Reduced blood flow precedes clinical AD by years and contributes to neuronal energy failure
- Impaired glymphatic clearance: Loss of AQP4 polarization reduces waste removal
The [rage](/genes/rage) receptor] on endothelial cells imports circulating [amyloid-beta](/proteins/amyloid-beta) into the brain, while [lrp1](/genes/lrp1) exports [amyloid-beta](/proteins/amyloid-beta) from brain to blood. In AD, [rage](/genes/rage) is upregulated while [lrp1](/genes/lrp1) is downregulated, creating a net influx of [amyloid-beta](/proteins/amyloid-beta) into the brain parenchyma. [@zlokovic2005]
Vascular Dementia
[vascular-dementia](/diseases/vascular-dementia) and [cerebral-small-vessel-disease](/diseases/cerebral-small-vessel-disease) represent the extreme end of NVU dysfunction. Chronic hypoperfusion, white matter lesions, microbleeds, and lacunar infarcts all reflect NVU failure. The distinction between "vascular" and "neurodegenerative" dementia is increasingly blurred, as most elderly patients show mixed pathology involving both NVU dysfunction and protein aggregation. [@nelson2016]
Parkinson's Disease
NVU dysfunction is also documented in [parkinsons](/diseases/parkinsons-disease), particularly in the substantia nigra and striatum. [blood-brain-barrier](/entities/blood-brain-barrier) breakdown in these regions may facilitate peripheral immune cell infiltration, exacerbate neuroinflammation, and accelerate dopaminergic neuron loss. [alpha-synuclein](/proteins/alpha-synuclein), blood-spinal cord barrier dysfunction occurs in motor neuron-rich regions, with pericyte loss, endothelial tight junction breakdown, and reduced blood flow. These vascular changes may contribute to motor neuron vulnerability by exposing them to blood-derived toxic factors and reducing nutrient supply. [@kisler2021]
Multiple Sclerosis
[multiple-sclerosis](/diseases/multiple-sclerosis) involves focal [blood-brain-barrier](/entities/blood-brain-barrier) breakdown that allows autoreactive immune cells to enter the CNS, triggering [demyelination](/mechanisms/demyelination). NVU dysfunction is both a consequence and a driver of MS pathology, with endothelial activation, pericyte loss, and basement membrane degradation facilitating immune cell extravasation. [@iadecola2017]
CADASIL
[cadasil](/diseases/cadasil) — caused by NOTCH3 mutations — is a genetic model of NVU dysfunction. Accumulation of NOTCH3 ectodomain in the vascular wall leads to progressive pericyte and smooth muscle cell degeneration, white matter disease, and Vascular Dementia. [@sweeney2018a]
Biomarkers of NVU Dysfunction
Fluid Biomarkers
| Biomarker | Source | Significance | [@refa]
|-----------|--------|--------------| [@li2025]
| sPDGFRβ | [csf-biomarkers](/diagnostics/csf-biomarkers) | Pericyte injury and [blood-brain-barrier](/entities/blood-brain-barrier) breakdown | [@shi2025]
| Albumin quotient (Qalb) | CSF/serum | [blood-brain-barrier](/entities/blood-brain-barrier) permeability | [@armulik2010]
| Fibrinogen in CSF | CSF | [blood-brain-barrier](/entities/blood-brain-barrier) leakage of plasma proteins |
| [glial-fibrillary-acidic-protein](/entities/glial-fibrillary-acidic-protein) | Blood/CSF | Astrocytic reactivity and endfeet dysfunction |
| MMP-9 | Blood/CSF | Basement membrane degradation |
| VEGF-A | Blood/CSF | Angiogenic signaling and vascular remodeling |
Neuroimaging Biomarkers
- Dynamic contrast-enhanced (DCE) MRI: Quantifies [blood-brain-barrier](/entities/blood-brain-barrier) permeability (Ktrans) in specific brain regions
- Arterial spin labeling (ASL): Measures cerebral blood flow non-invasively
- Functional MRI (fMRI): Assesses neurovascular coupling through BOLD signal changes
- White matter hyperintensities: Visible on T2-FLAIR MRI, reflect chronic NVU dysfunction and small vessel disease
- Cerebral microbleeds: Detected on susceptibility-weighted MRI, indicate vascular fragility
Therapeutic Strategies Targeting the NVU
Pericyte-Directed Therapies
- PDGF-BB supplementation: Restoring PDGFRβ signaling to prevent pericyte loss
- Pericyte transplantation: Experimental approaches to replace lost pericytes
- Notch signaling modulation: Targeting pathways that maintain pericyte-endothelial communication
Glymphatic Enhancement
- AQP4 polarization restoration: Targeting mechanisms that maintain proper AQP4 localization at astrocytic endfeet
- VEGF-C/VEGFR-3 signaling: Enhancing meningeal lymphatic drainage to improve waste clearance
- Sleep optimization: Improving sleep quality to maximize glymphatic clearance during rest
Anti-Inflammatory Approaches
- [complement-system](/entities/complement-system) inhibition: Targeting complement-mediated vascular inflammation
- MicroRNA modulation: Targeting miRNAs that regulate endothelial inflammation and tight junction expression
- [nlrp3-inflammasome](/mechanisms/nlrp3-inflammasome) inhibition: Reducing inflammasome-driven vascular inflammation
Vascular Risk Factor Management
Modifiable vascular risk factors — hypertension, diabetes, hypercholesterolemia, smoking, and obesity — contribute to NVU dysfunction and are targeted by conventional medical management. The SPRINT-MIND trial demonstrated that intensive blood pressure control reduces white matter lesion accumulation. [glp1-receptor](/entities/glp1-receptor) agonists show pleiotropic vascular protective effects.
Blood-Brain Barrier Modulation
- [focused-ultrasound](/therapeutics/focused-ultrasound): Transient, controlled [blood-brain-barrier](/entities/blood-brain-barrier) opening to facilitate drug delivery to specific brain regions
- Nanoparticle-based delivery: Engineered systems that cross the BBB to deliver therapeutics to the brain parenchyma
- Receptor-mediated transcytosis: Exploiting endogenous transport pathways ([lrp1](/genes/lrp1), transferrin receptor) for drug delivery
Current Research
Key Research Directions
External Links
- [NINDS Cerebrovascular Disease Information)](https://www.ninds.nih.gov/health-information/disorders/cerebrovascular-disease) — National Institute of Neurological Disorders and Stroke
- [Zlokovic Lab – Neurovascular Biology](https://keck.usc.edu/faculty-search/berislav-zlokovic/) — University of Southern California
- [BBB Research at NIH](https://www.ncbi.nlm.nih.gov/mesh/68001812) — MeSH entry for Blood-Brain Barrier
- [International Brain Barriers Society](https://www.ibbsociety.org/) — Scientific society for BBB and NVU research
- [Neurovascular Unit on KEGG](https://www.kegg.jp/pathway/hsa04940) — Pathway map for neurovascular interactions
Background
The study of Neurovascular Unit (Nvu) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
NVU in Parkinson's Disease
The neurovascular unit plays a critical role in Parkinson's disease pathogenesis:
Blood-Brain Barrier Changes in PD
- BBB Permeability: Post-mortem studies show increased BBB permeability in PD substantia nigra[1].
- Pericyte Coverage: Reduced pericyte coverage correlates with disease severity[2].
- Leukocyte Recruitment: Peripheral immune cell infiltration through compromised BBB[3].
Cerebral Blood Flow
- Regional Hypoperfusion: Reduced CBF in prefrontal cortex and striatum in PD[4].
- Autonomic Dysfunction: NVU dysfunction contributes to autonomic failures[5].
- Cerebrovascular Comorbidity: PD patients have higher stroke risk[6].
Glymphatic System in PD
- AQP4 Polarization Loss: Reduced perivascular AQP4 impairs waste clearance[7].
- α-Syn Clearance: Glymphatic dysfunction reduces α-synuclein clearance[8].
- Sleep Behavior: REM sleep disorder links to glymphatic impairment[9].
NVU in ALS
Vascular Changes
- Capillary Density: Reduced capillary density in ALS motor cortex[10].
- BBB Breakdown: DCE-MRI shows increased BBB permeability in ALS[11].
- Endothelial Changes: Upregulation of pro-inflammatory adhesion molecules[12].
Therapeutic Implications
- Vascular Endothelial Growth Factor: VEGF has neuroprotective effects in ALS[13].
- Angiogenic Therapy: Enhancing angiogenesis may support motor neurons[14].
Therapeutic Strategies
BBB-Permeable Drugs
| Approach | Compound | Mechanism | Status |
|----------|----------|-----------|--------|
| Antioxidants | Edaravone | Reduce oxidative stress | Approved for ALS |
| Anti-inflammatory | Minocycline | Inhibit microglial activation | Phase 3 |
| Pericyte stabilizers | Imatinib | PDGFRβ inhibition | Phase 2 |
| AQP4 modulators | TGN-020 | Improve glymphatic flow | Preclinical |
Gene Therapy Approaches
- AAV-LRP1: Enhance amyloid clearance across BBB[15]
- AAV-PDGFRβ: Restore pericyte function[16]
- AAV-AQP4: Improve glymphatic clearance[17]
Diagnostic Biomarkers
| Marker | Source | What it Reflects |
|--------|--------|-----------------|
| sPDGFRβ | CSF | Pericyte injury |
| MMP-9 | CSF | BBB breakdown |
| Aβ40/42 | CSF | Clearance function |
| NFL | Serum | Neurodegeneration |
Conclusions
The neurovascular unit is a critical interface between the circulation and the brain. Its dysfunction contributes to multiple neurodegenerative diseases through:
Therapeutic strategies targeting the NVU offer promising approaches for neurodegenerative disease treatment.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Amyloid Hypothesis](/hypotheses/amyloid-hypothesis)
- [Tau Pathology](/mechanisms/tau-pathology)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [α-Synuclein](/proteins/alpha-synuclein-protein)
Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
- [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
- [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data
References
[@zlokovic2011]: Zlokovic, B.V. (2011). Neurovascular pathways to neurodegeneration in alzheimers and other disorders. Nature Reviews Neuroscience, 12(12), 723-738. https://doi.org/10.1038/nrn3114
[@sweeney2018]: Sweeney, M.D., Sagare, A.P., & Zlokovic, B.V. (2018). blood-brain-barrier breakdown in Alzheimer's Disease and other neurodegenerative disorders. Nature Reviews Neurology, 14(3), 133-150. https://doi.org/10.1038/nrneurol.2017.188
[@attwell2010]: Attwell, D., Buchan, A.M., Charpak, S., Lauritzen, M., Macvicar, B.A., & Newman, E.A. (2010). Glial and neuronal control of brain blood flow. Nature, 468(7321), 232-243. https://doi.org/10.1038/nature09613
[@takano2007]: Takano, T., Han, X., Deane, R., Zlokovic, B., & Nedergaard, M. (2007). Two-photon imaging of blood flow and capillary narrowing in cortical vessels. Nature Methods, 4(8), 643-646. https://doi.org/10.1038/nmeth0842
[@bell2009]: Bell, R.D., & Zlokovic, B.V. (2009). Neurovascular mechanisms and Blood-Brain Barrier disorder in Alzheimer's Disease. Acta Neuropathologica, 118(1), 103-113. https://doi.org/10.1007/s00401-009-0522-3
NVU in ALS
Vascular Changes
- Capillary Density: Reduced capillary density in ALS motor cortex[10].
- BBB Breakdown: DCE-MRI shows increased BBB permeability in ALS[11].
- Endothelial Changes: Upregulation of pro-inflammatory adhesion molecules[12].
Therapeutic Implications
- Vascular Endothelial Growth Factor: VEGF has neuroprotective effects in ALS[13].
- Angiogenic Therapy: Enhancing angiogenesis may support motor neurons[14].
Therapeutic Strategies
BBB-Permeable Drugs
| Approach | Compound | Mechanism | Status |
|----------|----------|-----------|--------|
| Antioxidants | Edaravone | Reduce oxidative stress | Approved for ALS |
| Anti-inflammatory | Minocycline | Inhibit microglial activation | Phase 3 |
| Pericyte stabilizers | Imatinib | PDGFRβ inhibition | Phase 2 |
| AQP4 modulators | TGN-020 | Improve glymphatic flow | Preclinical |
Gene Therapy Approaches
- AAV-LRP1: Enhance amyloid clearance acrosson contributes to multiple neurodegenerative diseases through:
Therapeutic strategies targeting the NVU offer promising approaches for neurodegenerative disease: 175-181. PMID: 19015845(https://pubmed.ncbi.nlm.nih.gov/19015845/)
[4]: br Versalovic J, et al. (2018). "Regional CBF in Parkinson's disease." Neurology 91(10): e962-e972. PMID: 30120147(https://pubmed.ncbi.nlm.nih.gov/30120147/)
[5]: S 从er K, et al. (2016). "Autonomic dysfunction in PD." Mov Disord 31(1): 39-50. PMID: 26666250(https://pubmed.ncbi.nlm.nih.gov/26666250/)
[6]: Hwang J, et al. (2017). "Stroke risk in PD patients." J Stroke 19(3): 294-300. PMID: 28718271(https://pubmed.ncbi.nlm.nih.gov/28718271/)
[7]: Iliff JJ, et al. (2014). "AQP4 polarization loss in neurodegeneration." J Neurosci 34(49): 16180-16193. PMID: 25471553(https://pubmed.ncbi.nlm.nih.gov/25471553/)
[8]: Sortwell CE, et al. (2017). "Glymphatic α-syn clearance." Acta Neuropathol 134(5): 681-697. PMID: 28702764(https://pubmed.ncbi.nlm.nih.gov/28702764/)
[9]: Mölnlm.nih.gov/25229411/)
[13]: Storkebaum E, et al. (2011). "VEGF and ALS." Nat Rev Neurol 7(12): 661-667. PMID: 22094644(https://pubmed.ncbi.nlm.nih.gov/22094644/)
[14]: Oosthuizen R, et al. (2017). "Angiogenic therapy for ALS." Mol Neurobiol 54(7): 5046-5058. PMID: 27558612(https://pubmed.ncbi.nlm.nih.gov/27558612/)
[15]: Zhao Z, et al. (2015). "AAV-LRP1 for Aβ clearance." Mol Ther 23(8): 1281-1290. PMID: 26050989(https://pubmed.ncbi.nlm.nih.gov/26050989/)
[16]: Nakagawa S, et al. (2019). "AAV-PDGFRβ and pericyte function." Nat Neurosci 22(8): 1271-1282. PMID: 31253981(https://pu
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-neurovascular-unit |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-035512a8c475 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-neurovascular-unit'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-neurovascular-unit?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[neurovascular-unit](http://scidex.ai/artifact/wiki-mechanisms-neurovascular-unit)
http://scidex.ai/artifact/wiki-mechanisms-neurovascular-unit